Considerations for Method Validation

Susan J. Schniepp, distinguished fellow for Regulatory Compliance Associates, and Shiri Hechter, senior lab operations manager for Nelson Laboratories, provide a simple approach to validating analytical methods.

Q. How can an analytical method be validated?

A. When using an analytical method published in a pharmacopeia, the method is considered validated and it just needs to be verified under actual conditions of use (1). However, when using analytical methods for routine testing that are not published in the pharmacopeias, it is expected that the method would be validated.

The United States Pharmacopeia defines validation of an analytical procedure as “the process by which it is established, by laboratory studies, that the performance characteristics of the procedure meet the requirements for the intended analytical applications” (2). The European Directorate for the Quality of Medicines and HealthCare (EDQM), which publishes the European Pharmacopoeia (Ph. Eur.), takes a similar approach stating, “This chapter defines the different analytical situations (categories) which might occur in an OMCL [official medicines control laboratories] and the corresponding validation characteristics which should be considered. Refer to the current version of the ICH [International Council for Harmonisation] guideline on ‘Validation of Analytical Procedures: Text and Methodology (Q2)’ ” (3).

The following examples of industry guidelines provide rationale and approach when validating analytical methods:

• The United States Pharmacopeia–National Formulary (USP–NF) general chapter <1225> Validation of Compendial Procedures (2)
• PA/PH/OMCL (13) 82 R5, Validation/Verification of Analytical Procedures revised in July 2020 (3)
• FDA’s Analytical Procedures and Methods Validation for Drugs and Biologics, Guidance for Industry, July 2015 (4)
• ICH guideline Q2(R2) on validation of analytical procedures (currently under public consultation) published March 31, 2022 (5).

These documents are inter-connected because they reference each other and the approach they define is based on defining “Typical analytical performance characteristics that should be considered in the validation of the types of procedures …” (2). In USP General Chapter <1225>, some typical performance characteristics referred to are accuracy, precision, specificity, detection limit, quantitation limit, linearity, range, and robustness. These characteristics should all be considered when determining the validation approach for any analytical procedure.

USP <1225> aims at compendial procedures that include routine tests on raw materials and finished products. The FDA guidance covers new drug applications, abbreviated new drug applications, biologics license applications, and supplements to these applications. Definitions, data elements, and acceptance levels are well documented in these publications. Depending on the objectives of the method, data elements could vary. For example, USP <1225> defines four categories for consideration. For example, the chapter indicates that Category I–Assay, does not need to have detection limit, whereas Category II–Limit Tests, requires detection limit. The full data elements required for validation are detailed in Table 2 in USP <1225>. Similar instructions can be found in ICH guideline Q2(R2) table. The OMCL (3) document also provides reference tables that discusses the source of the method (i.e., Ph. Eur. method, validated method form a manufacturer, etc.) and the validation requirements needed to ensure it is an appropriate method for its intended use.

In summary, when performing analytical method validation, validation parameters and elements are determined based on the analytical test method and the intended analytical application.

References

1. Schniepp, S.J. and Lynn, S.J. Verifying Compendial Methods. Pharm.Technol. 2022 46 (4).
2. USP. <1225> Validation Of Compendial Procedures. USP 45 - NF 40, 2022.
3. General European OMCL Network (GEON), PA/PH/OMCL (13) 82 R5, July 2022.
4. FDA. Analytical Procedures and Methods Validation for Drugs and Biologics–Guidance for Industry (2015).
5. ICH. Q2(R2) Analytical Procedure Development and Revison of Q2 (R1) Analytical Validation. Currently under public consultation (ICH, March 31, 2022).

Article details

Pharmaceutical Technology
Vol. 47, No. 2
February 2023
Page: 34

Citation

When referring to this article, please cite it as Schniepp, S.J. and Hechter, S. Considerations for Method Validation. Pharmaceutical Technology 2023 47 (2) p. 34.